CRIS Current Research Information System

GIANNI, CATERINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.472
NA - Nord America 546
EU - Europa 320
SA - Sud America 55
AF - Africa 39
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 2.437
Salva come PNG Salva come JPEG
Nazione #
VN - Vietnam 560
US - Stati Uniti d'America 521
SG - Singapore 263
CN - Cina 237
IT - Italia 138
HK - Hong Kong 135
BD - Bangladesh 102
KR - Corea 58
FR - Francia 37
BR - Brasile 31
IN - India 29
DE - Germania 25
NL - Olanda 23
JP - Giappone 20
FI - Finlandia 19
CA - Canada 15
TH - Thailandia 14
CI - Costa d'Avorio 13
PH - Filippine 13
SE - Svezia 13
IE - Irlanda 11
GB - Regno Unito 10
SC - Seychelles 9
AT - Austria 8
RU - Federazione Russa 8
AR - Argentina 7
ID - Indonesia 7
GH - Ghana 6
MX - Messico 6
CH - Svizzera 5
JO - Giordania 5
CL - Cile 4
LT - Lituania 4
TW - Taiwan 4
VE - Venezuela 4
AU - Australia 3
BE - Belgio 3
BG - Bulgaria 3
BO - Bolivia 3
ES - Italia 3
IQ - Iraq 3
PK - Pakistan 3
RO - Romania 3
TG - Togo 3
ZA - Sudafrica 3
CO - Colombia 2
EC - Ecuador 2
JM - Giamaica 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
NP - Nepal 2
OM - Oman 2
PL - Polonia 2
SA - Arabia Saudita 2
TR - Turchia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AZ - Azerbaigian 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
EG - Egitto 1
GR - Grecia 1
GY - Guiana 1
HR - Croazia 1
IL - Israele 1
KW - Kuwait 1
LC - Santa Lucia 1
MA - Marocco 1
MG - Madagascar 1
MM - Myanmar 1
MT - Malta 1
MY - Malesia 1
NG - Nigeria 1
PY - Paraguay 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
UA - Ucraina 1
UZ - Uzbekistan 1
Totale 2.437
Salva come PNG Salva come JPEG
Città #
Singapore 201
Ho Chi Minh City 149
Hanoi 135
San Jose 129
Hong Kong 124
Hefei 99
Ashburn 67
Seoul 49
Council Bluffs 39
New York 39
Los Angeles 34
Santa Clara 30
Bologna 23
Da Nang 21
Lauterbourg 21
Haiphong 17
Abidjan 13
Beijing 13
Tokyo 13
Buffalo 12
São Paulo 12
Boardman 11
Dublin 11
Ha Long 10
Helsinki 10
Hải Dương 10
Rome 10
Bengaluru 9
Lappeenranta 9
Thái Nguyên 9
Amsterdam 8
Biên Hòa 8
Bắc Giang 8
Frankfurt am Main 7
Accra 6
Bangkok 6
Dallas 6
Princeton 6
Can Tho 5
Chandler 5
Charlotte 5
Des Moines 5
Hangzhou 5
Jakarta 5
Milan 5
Modena 5
Quận Bình Thạnh 5
Thái Bình 5
Vienna 5
Điện Bàn 5
Amman 4
Mexico City 4
Quận Phú Nhuận 4
Ravenna 4
Southend 4
Vũng Tàu 4
Baghdad 3
Bắc Ninh 3
Caracas 3
Chicago 3
Cleveland 3
Delhi 3
Guangzhou 3
Hyderabad 3
La Paz 3
Lomé 3
Long Xuyen 3
Montreal 3
Monzuno 3
Munich 3
Nha Trang 3
Ninh Bình 3
Nuremberg 3
Paris 3
Phủ Lý 3
Quận Sáu 3
Reggio Emilia 3
San Diego 3
Shanghai 3
Sofia 3
Toronto 3
Turin 3
Vinh 3
Zurich 3
Acalanes Ridge 2
Almaty 2
Bari 2
Bozeman 2
Bucharest 2
Bình Phước 2
Bạc Liêu 2
Chennai 2
DeKalb 2
Fairfield 2
Gaziantep 2
Genoa 2
Guayaquil 2
Huế 2
Jeonju 2
Johannesburg 2
Totale 1.584
Salva come PNG Salva come JPEG
Nome #
Exploring the promoter regions of cancer predisposition genes in patients with triple-negative breast cancer reveals the presence of rare germline variants 351
Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer 170
Primary Mediastinal and Testicular Germ Cell Tumors in Adolescents and Adults: A Comparison of Genomic Alterations and Clinical Implications 156
Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure 152
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives 148
Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma 136
Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy 97
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients 96
An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA 91
Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trial 89
Local treatment for oligoprogressive metastatic sites of breast cancer: efficacy, toxicities and future perspectives 75
Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors 75
Recurrent pneumothorax in a patient with liposarcoma as either a complication of lung micrometastasis or a potential adverse event from antibiotic therapy: A case report 73
Impact of circulating tumor DNA (ctDNA) surveillance on clinical care for patients with stage I-III breast cancer: Findings from a multi-institutional study 63
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer 62
Pharmacological Prevention in Breast Cancer: Current Evidence, Challenges, and Future Directions 56
ROLE OF HPV VACCINATION AFTER CARCINOMA IN SITU OF CERVIX UTERI (CIN) IN REAL-WORLD PATIENTS 54
Inflammatory Biomarkers for Outcome Prediction in Patients With Metastatic Testicular Cancer 53
Mapping breast cancer therapy with circulating tumor cells: The expert perspective 50
Hormonal Therapy For Endometriosis And The Risk Of Endometriosis-Associated Gynecologic Cancers: A Propensity Score-Adjusted Real-World Data Study 46
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study 44
Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors 37
Investigating biochemical markers of Acupuncture's effectiveness in managing climacteric syndrome in breast cancer patients: the FLAIR study 36
Circulating tumor DNA detection of local recurrence in a patient with early stage triple-negative breast cancer 35
Corrigendum to “Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives” [Crit. Rev. Oncol./Hematol. 181 (2023) 103900] (Critical Reviews in Oncology / Hematology (2023) 181, (S1040842822003249), (10.1016/j.critrevonc.2022.103900)) 33
Circulating tumor cells et al.: towards a comprehensive liquid biopsy approach in breast cancer 30
Modeling the management of patients with human epidermal growth factor receptor 2-positive breast cancer with liquid biopsy: the future of precision medicine 28
Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysis 27
Redefining Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer in the Era of Novel Antibody-Drug Conjugates 26
Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer 23
Corrigendum to “Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: Biomarkers and beyond” [Crit. Rev. Oncol./Hematol. 200C (2024) 104404](S1040842824001471)(10.1016/j.critrevonc.2024.104404) 21
Quantitative HER2 profiling on circulating tumor cells using an EpCAM-independent platform in metastatic breast cancer 21
Adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: one fits all? 17
Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic Review 17
Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma 14
Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors 10
Totale 2.512
Salva come PNG Salva come JPEG
Categoria #
all - tutte 5.451
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.451
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202239 0 0 0 3 1 1 5 2 0 7 13 7
2022/202341 3 5 1 4 4 2 3 1 10 1 2 5
2023/202442 2 3 0 0 2 5 7 5 8 9 0 1
2024/2025273 17 22 24 24 24 15 7 12 9 21 30 68
2025/20262.117 309 114 79 68 61 22 318 112 513 200 177 144
Totale 2.512